We need to reduce pathogens in indoor spaces
CounterAct™ fixtures contain Ushio Inc.’s Care222® lamps that emit far-UVC light that has been shown in the lab to inactivate more than 99% of pathogens, including the SARS-CoV-2 coronavirus that causes COVID-19. The far-UVC 222nm light the lamps emit destroys the DNA and RNA of bacteria and viruses, inactivating them so they are unable to reproduce.
Not all UVC light is created equal
Far-UVC is a type of UV light that has long been used to disinfect spaces. But the longer wavelength (254nm) UVC light that’s traditionally used for disinfection presents a health risk to our eyes and skin, so can’t be used when people are present.
What’s new is the discovery and application of far-UVC 222nm light, a sweet spot on the UV spectrum, to effectively inactivate pathogens with people present without the need for protective gear. It’s technology that’s safer for use in occupied indoor spaces that allows for automated, continual pathogen-reduction.
But don’t just take our word for it, download our far-UVC light white paper and learn about the science and the studies behind the Care222 technology in our CounterAct products.
Far-UVC white paper
Let’s return to the places we love
Christie CounterAct™ commercial UV disinfection fixtures contain patented Care222® technology that emits filtered far-UVC 222nm light, designed to neutralize pathogens with people present while meeting established safety guidelines. Care222 is also the world’s first UVC technology with a proprietary optical filter that blocks potentially harmful longer (>230nm) UVC wavelengths from being emitted.
Now, and for the future
Urbanization, worldwide population growth, and global travel contribute to diverse contact among people, livestock, and wildlife, increasing the frequency and transmission of new pathogens that may harm us. We need safe and effective disinfection technology that reduces pathogens now, and for the future.
All references to “disinfect”, “disinfecting” and “disinfection” refer generally to the reduction of pathogenic bioburden and are not intended to refer to any specific definition as may be used by any governmental or regulatory authority including the U.S. Food and Drug Administration and the U.S. Environmental Protection Agency. Christie CounterAct products with patented Care222 technology are not medical devices and are not to be used as or for medical devices. The pathogen-reducing efficacy of Christie CounterAct products and their use in occupied spaces is dependent on many site-specific factors as well as proper installation and operation within specifications and in accordance with American Conference of Governmental Institutional Hygienist (ACGIH) guidelines. Professional installation is recommended for Christie CounterAct products. “Christie” is a trademark of Christie Digital Systems USA, Inc., registered in the United States of America and other countries. This product uses Care222® technology developed by Ushio Inc. The Care222® is a trademark or registered trademark of Ushio Inc. and Ushio America, Inc.